The translation of ALK-inhibitors in locally advanced NSCLC patients with EML4-ALK fusion will largely depend on a better understanding of the effects elicited by this novel class of drugs in combination with radiotherapy. This evidence concerns the gene EML4 and non-small cell lung carcinoma.